TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18356684

Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine (160 mg valsartan plus amlodipine titrated from 2.5 to 10 mg)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Atenolol/Amlodipine (100 mg atenolol plus amlodipine titrated from 2.5 to 10 mg)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine
Number of subjects: 296

Group type: COMPARATOR
Intervention: Atenolol/Amlodipine
Number of subjects: 296
Study: 16275694

Group type: EXPERIMENTAL
Intervention: Medication compliance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary sodium restrictions compliance
Number of subjects: 0
Study: 12839658

Group type: EXPERIMENTAL
Intervention: Worksite-based intervention program at CISC
Number of subjects: 110000

Group type: COMPARATOR
Intervention: Reference groups (control)
Number of subjects: 110000
Study: 14530932

Group type: EXPERIMENTAL
Intervention: Droperidol 50 microg.kg(‐1) (maximum dose, 2.5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study: 8876342

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 . day‐1 x 5 g Cr.H2O + 2 g sucrose)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (4 . day‐1 x 5 g Polycose + 2 g sucrose)
Number of subjects: 32
Study: 1653913

Group type: EXPERIMENTAL
Intervention: Milacemide (glycine prodrug)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6654627

Group type: EXPERIMENTAL
Intervention: Atropine (3 X 0.66 mg)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Atropine + Cyproheptadine (3 X 4 mg)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Carbenoxolone (3 X 100-3 X 50 mg)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Atropine + Carbenoxolone
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 31717505

Group type: EXPERIMENTAL
Intervention: High SBP_Cv (≥11.9%)
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: High DBP_Cv (≥22.4%)
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: High MAP_Cv (≥13.6%)
Number of subjects: 835
Study: 29205463

Group type: EXPERIMENTAL
Intervention: Spontaneous vaginal birth
Number of subjects: 880

Group type: COMPARATOR
Intervention: Emergency repeat cesarean
Number of subjects: 880

Group type: COMPARATOR
Intervention: Postnatal readmission of the mother
Number of subjects: 880

Group type: COMPARATOR
Intervention: Public health insurance
Number of subjects: 880

Group type: COMPARATOR
Intervention: Low antenatal HRQoL score
Number of subjects: 880
Study: 26944891

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of 2 units of botulinum toxin type A (BTX‐A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of 4 units of botulinum toxin type A (BTX‐A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both dosages of BTX‐A (2 units and 4 units)
Number of subjects: 42
Study: 25252807

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy intervention (CBTi) for fear of falling
Number of subjects: 25
Study: 22698066

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg.kg(‐1) administered at 1‐2 post‐tetanic count (deep blockade)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Neostigmine 50 μg.kg(‐1) plus atropine 10 μg.kg(‐1) administered at the re‐appearance of the second twitch of a train‐of‐four stimulation (moderate blockade)
Number of subjects: 131
Study: 20204689

Group type: EXPERIMENTAL
Intervention: 16-week group intervention designed to teach appropriate social behavior
Number of subjects: 44

Group type: COMPARATOR
Intervention: Wait list (control group)
Number of subjects: 44
Study: 18607562

Group type: EXPERIMENTAL
Intervention: Proportional assist ventilation with load-adjustable gain factors (PAV+)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Pressure support ventilation (PS)
Number of subjects: 208
Study: 16135188

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient (MMN) supplementation
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 499

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 499
Study: 11798370

Group type: EXPERIMENTAL
Intervention: EDTA chelation therapy (40 mg/kg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 10472237

Group type: EXPERIMENTAL
Intervention: Clonidine 3 micrograms kg‐1
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 8568042

Group type: EXPERIMENTAL
Intervention: Low-pass filtered white noise with cue tones at target frequencies (1000, 1259, 1585, and 2000 Hz) presented randomly on trials. Target frequency was the same as cue frequency on 60% of trials.
Number of subjects: 4

Group type: COMPARATOR
Intervention: Fixed frequency tone condition where cue frequency always equaled target frequency and target was attenuated according to auditory filter attenuation at probe frequency.
Number of subjects: 4
Study: 1912739

Group type: EXPERIMENTAL
Intervention: GUIDELINES
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Manual
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Therapist
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Changes from baseline in GGT, MCV, and the Digit Symbol Test
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Therapist experience
Number of subjects: 96
Study: 7094972

Group type: EXPERIMENTAL
Intervention: Neomycin sulphate 1.5 g/d for 8 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Neomycin sulphate 1.5 g/d and d‐thyroxine 6 mg/d for 8 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Neomycin sulphate 1.5 g/d for up to 13 months
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Neomycin sulphate 1.5 g/d for 4‐8 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: d‐thyroxine
Number of subjects: 19
Study: 29769176

Group type: EXPERIMENTAL
Intervention: Formula feeding before, during, and after vaccination
Number of subjects: 48
Study: 26446912

Group type: EXPERIMENTAL
Intervention: All-on-4
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All-on-6
Number of subjects: 40

Group type: COMPARATOR
Intervention: All-on-4 and All-on-6
Number of subjects: 40
Study: 25048848

Group type: EXPERIMENTAL
Intervention: Topical 5% 250 mg imiquimod ointment followed by intradermal TIV
Number of subjects: 91

Group type: COMPARATOR
Intervention: Topical aqueous-cream followed by intramuscular TIV
Number of subjects: 91

Group type: COMPARATOR
Intervention: Topical aqueous-cream followed by intradermal TIV
Number of subjects: 91
Study: 22518940

Group type: EXPERIMENTAL
Intervention: Trained participants
Number of subjects: 12

Group type: COMPARATOR
Intervention: Untrained participants
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trained participants at 120 rpm
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trained participants at 90 rpm
Number of subjects: 12
Study: 20688729

Group type: EXPERIMENTAL
Intervention: +2.00-D add over manifest correction
Number of subjects: 83

Group type: COMPARATOR
Intervention: Single-vision lenses (SVLs)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Progressive addition lenses (PALs)
Number of subjects: 83
Study: 18471387

Group type: EXPERIMENTAL
Intervention: 100 mL of contrast agent
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 80 mL of contrast agent
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 60 mL of contrast agent
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 40 mL of physiological serum at a rate of 4 ml/s
Number of subjects: 63
Study: 15684301

Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (15 beats/min faster than mean baseline nocturnal cardiac frequency) for 1 month
Number of subjects: 17

Group type: COMPARATOR
Intervention: Spontaneous rhythm for 1 month
Number of subjects: 17
Study: 12915640

Group type: EXPERIMENTAL
Intervention: 3 IU GH/m(2).d (approximately 0.033 mg/kg.d)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 6 IU GH/m(2).d (approximately 0.067 mg/kg.d)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (non-GH-treated)
Number of subjects: 54
Study: 10555031

Group type: COMPARATOR
Intervention: Serum COMP levels in OA group (1,208.57 ± 487.47 ng/ml)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Serum COMP levels in age > or = 65 group (1,302.1 ± 496.7 ng/ml)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Serum COMP levels increase with knee OA K/L grade
Number of subjects: 291

Group type: COMPARATOR
Intervention: Serum COMP levels increase with knee OA laterality
Number of subjects: 291

Group type: COMPARATOR
Intervention: Serum COMP levels increase with number of knee and hip joints involved
Number of subjects: 291
Study: 8947785

Group type: EXPERIMENTAL
Intervention: Active stimulation (inhalation through the nose with stimuli delivered synchronously)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Passive stimulation (mouth-breathing with stimuli delivered asynchronously)
Number of subjects: 12
Study: 1750602

Group type: EXPERIMENTAL
Intervention: Single-dose oral famotidine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Double-dose oral ranitidine
Number of subjects: 32
Study: 7044932

Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30954641

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 55
Study: 27913991

Group type: EXPERIMENTAL
Intervention: Preservative-free tafluprost
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Preservative-free dorzolamide/timolol fixed combination (triple PF regimen)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Preserved latanoprost
Number of subjects: 43
Study: 25766854

Group type: EXPERIMENTAL
Intervention: Point-of-care monitoring (n=55)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Usual monitoring routines (n=48)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Point-of-care monitoring
Number of subjects: 103
Study: 23799935

Group type: EXPERIMENTAL
Intervention: Omalizumab + Specific Immunotherapy (SIT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Specific Immunotherapy (SIT) + Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Omalizumab + SIT
Number of subjects: 140

Group type: COMPARATOR
Intervention: SIT + Placebo
Number of subjects: 140
Study: 21868795

Group type: EXPERIMENTAL
Intervention: DermaStream system (treatment group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (traditional methods)
Number of subjects: 15
Study: 19195259

Group type: EXPERIMENTAL
Intervention: Pulse low-intensity electromagnetic field (PLIMF) therapy, induction of 10 mT, frequency of 25 Hz, duration of 30 min, started in the 7th week after injury and lasted for 4 weeks.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no PLIMF therapy), only exercise and range of motion therapy.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: PLIMF therapy in the experimental group.
Number of subjects: 29
Study: 16923452

Group type: EXPERIMENTAL
Intervention: Colesevelam HCl (3.75 g/day for 6 weeks)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Colesevelam HCl
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15453925

Group type: EXPERIMENTAL
Intervention: CVPP plus involved-field radiotherapy (IFRT) in phase 1 (1968-1985)
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: Reinforced CVPP plus IFRT in phase 2 (1986-1996)
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: ABVD plus IFRT in phase 3 (1997-2003)
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: CVPP plus IFRT in phase 1 for clinical stage III/IV
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: Reinforced CVPP plus IFRT in phase 2 for clinical stage III/IV
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: ABVD plus IFRT in phase 3 for clinical stage III/IV
Number of subjects: 1254
Study: 11305069

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation-based stress reduction program (1.5 h each week for 7 weeks, plus daily home meditation practice)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation-based stress reduction program
Number of subjects: 89
Study: 9280254

Group type: EXPERIMENTAL
Intervention: Resovist (4 micromol Fe/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Resovist (8 micromol Fe/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Resovist (16 micromol Fe/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Resovist (all doses)
Number of subjects: 36
Study: 7712677

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion (8-hour initial infusion followed by 40-hour infusion)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (after 8-hour lidocaine infusion)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patients with initial ventricular fibrillation (not included in randomized study)
Number of subjects: 200
Study: 2565329

Group type: EXPERIMENTAL
Intervention: NAD (nadolol, 80 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: AT (atenolol, 100 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: PLAC (placebo)
Number of subjects: 8
Study: 1009290

Group type: EXPERIMENTAL
Intervention: Thought-disordered group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-thought-disordered group
Number of subjects: 2
Study: 31833786

Group type: EXPERIMENTAL
Intervention: isCGM
Number of subjects: 20
Study: 31757033

Group type: EXPERIMENTAL
Intervention: High-dose GSPE (400 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-dose GSPE (200 mg/day)
Number of subjects: 30
Study: 26069290

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 528

Group type: COMPARATOR
Intervention: Placebo or Best Available Therapy
Number of subjects: 528

Group type: COMPARATOR
Intervention: Crossover-adjusted Control
Number of subjects: 528
Study: 23364015

Group type: EXPERIMENTAL
Intervention: Diet Beverages (DBs)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Water
Number of subjects: 210
Study: 21875472

Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine 1000 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine 2000 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Original intravesical chemotherapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Gemcitabine (combined groups A and B)
Number of subjects: 72
Study: 17403597

Group type: EXPERIMENTAL
Intervention: In vivo exposure to spider
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaginal exposure to spider
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulations of uncontrollability, unpredictability, and dangerousness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptions of spiders as uncontrollable, unpredictable, and dangerous
Number of subjects: 0
Study: 16961291

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 300 mg three times daily
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (10% glucose, Vitamin C, and Inosine)
Number of subjects: 68
Study: 12965314

Group type: EXPERIMENTAL
Intervention: Preop‐TEA (8 mL of 0.25% bupivacaine plus fentanyl 50 microg in 2 mL administered preoperatively)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Postop‐TEA (no medication administered preoperatively and intraoperatively, postoperative analgesia maintained with patient‐controlled epidural analgesia with bupivacaine and fentanyl solution)
Number of subjects: 61
Study: 10852444

Group type: EXPERIMENTAL
Intervention: Hypoglycemic clamp of 2.9 +/‐ 0.1 mmol/L after euglycemia (5.1 +/‐ 0.1 mmol/L) on day 1
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycemia of 3.9, 3.3, and 2.9 +/‐ 0.1 mmol/L
Number of subjects: 15

Group type: COMPARATOR
Intervention: Identical day 1 hypoglycemia of 3.9, 3.3, and 2.9 +/‐ 0.1 mmol/L
Number of subjects: 15
Study: 8973428

Group type: COMPARATOR
Intervention: Nadolol alone
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Nadolol plus isosorbide mononitrate
Number of subjects: 146
Study: 1733145

Group type: EXPERIMENTAL
Intervention: JNIH-6 (two-component vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JNIH-7 (monocomponent pertussis toxoid vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6501058

Group type: EXPERIMENTAL
Intervention: Intracapsular extraction
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Extracapsular extraction
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: On-the-table capsulotomy
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: In-the-bag implantation without on-the-table capsulotomy
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Anterior-chamber-angle-fixated lenses
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 138
Study: 31256014

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions, two times per week)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 31303281

Group type: EXPERIMENTAL
Intervention: Lusutrombopag (2 mg) in fasted state
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lusutrombopag (2 mg) in fed state
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lusutrombopag (0.75 mg) in fasted state
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lusutrombopag (0.75 mg) in fed state
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lusutrombopag (0.75 mg) with calcium carbonate in fasted state
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lusutrombopag (4 mg) in fasted state
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lusutrombopag (4 mg) in fed state
Number of subjects: 48
Study: 29879254

Group type: EXPERIMENTAL
Intervention: Nimni Cream by Hydropeptide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27006014

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lateral femoral cutaneous nerve (LFCN) block with 8 ml of ropivacaine, 7.5 mg/ml (Group Ropivacaine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo with 8 ml of saline (Group Placebo)
Number of subjects: 100
Study: 24631129

Group type: EXPERIMENTAL
Intervention: ITCA 650 (20, 40, 60 or 80 μg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ITCA 650 (80 μg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ITCA 650 (not specified)
Number of subjects: 0
Study: 22446171

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g daily for 8 weeks
Number of subjects: 20
Study: 20851308

Group type: EXPERIMENTAL
Intervention: Individualized nutritional care for 6 months
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care of the health services
Number of subjects: 241
Study: 17164313

Group type: EXPERIMENTAL
Intervention: Gastric banding surgery
Number of subjects: 33

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 33
Study: 16344227

Group type: EXPERIMENTAL
Intervention: Exercise myocardial perfusion single photon emission computed tomography (MPS)
Number of subjects: 1122

Group type: EXPERIMENTAL
Intervention: Exercise-induced ST depression (3 mm or greater)
Number of subjects: 1122

Group type: EXPERIMENTAL
Intervention: % myo (percentage of myocardium involved with stress defects)
Number of subjects: 1122

Group type: EXPERIMENTAL
Intervention: Exercise-induced ST depression
Number of subjects: 1122
Study: 12017402

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily at bedtime
Number of subjects: 681

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 681
Study: 9823076

Group type: EXPERIMENTAL
Intervention: Composite inlays cemented with All-Bond 2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Composite inlays cemented with Geristore
Number of subjects: 50
Study: 7650122

Group type: EXPERIMENTAL
Intervention: Goserelin and human menopausal gonadotrophin (HMG)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Clomiphene citrate and human menopausal gonadotrophin (HMG)
Number of subjects: 300
Study: 1978496

Group type: EXPERIMENTAL
Intervention: Remoxipride (low dose: 30-90 mg daily)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Remoxipride (middle dose: 120-240 mg daily)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Remoxipride (high dose: 300-600 mg daily)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Haloperidol (15-45 mg daily)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Remoxipride (all doses)
Number of subjects: 242
Study: 580070

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CVP: cyclophosphamide, vincristine, and prednisone)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Successive single agent chemotherapy (C-V-P: cyclophosphamide, vincristine, and prednisone used successively)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CVP)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Successive single agent chemotherapy (C-V-P)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Neither regimen (CVP or C-V-P)
Number of subjects: 53
Study: 31640632

Group type: EXPERIMENTAL
Intervention: CBT plus standard medical care (SMC)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Standard medical care (SMC) alone
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: CBT plus SMC
Number of subjects: 322

Group type: COMPARATOR
Intervention: SMC alone
Number of subjects: 322
Study: 29324911

Group type: EXPERIMENTAL
Intervention: Surgical resection with IORT (Group B)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Surgical resection (Group A)
Number of subjects: 56
Study: 25863654

Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 822

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 822
Study: 23864097

Group type: EXPERIMENTAL
Intervention: CAPEOX and bevacizumab
Number of subjects: 667

Group type: COMPARATOR
Intervention: CAPEOX
Number of subjects: 667
Study: 21770805

Group type: EXPERIMENTAL
Intervention: Reading Center (RC) cup-to-disc ratio (CDR) assessment from stereoscopic photographs
Number of subjects: 479

Group type: COMPARATOR
Intervention: Clinical estimation of CDR by ophthalmologists via dilated biomicroscopy
Number of subjects: 479
Study: 19255389

Group type: EXPERIMENTAL
Intervention: Asthma coach intervention
Number of subjects: 306

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306